Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
•Development of lead drug candidate NYR-BI03 continues to advance:
-Preclinical efficacy study demonstrated 86% cardioprotective effect following myocardial ischemia reperfusion injury.
-Good Laboratory Practice safety studies completed.
-Phase Ia Clinical Trial regulatory package submitted to Human Research Ethics Committee(HREC).
•Sound financial position:
-Fully subscribed placement successfully raised AU$3.29 million (before costs).
-Securities Purchase Plan raised AU$0.09 million (before costs)
-R&D tax rebate of AU$1.24 million received.
-Additional AU$0.07 million (before costs) to be received in March 2025 quarter from Non-Executive Director participation, subject to CDI holder approval at February 2025 EGM.
-Cash position of AU$5.71 million at 31 December 2024.